Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $87
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad maintains an Overweight rating on Dr Reddy's Laboratories (NYSE:RDY) and raises the price target from $81 to $87.
July 30, 2024 | 11:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Balaji Prasad maintains an Overweight rating on Dr Reddy's Laboratories and raises the price target from $81 to $87.
The raised price target and maintained Overweight rating from Barclays is a positive signal for investors, indicating confidence in the company's future performance. This is likely to have a positive short-term impact on RDY's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100